Efficacy, Safety, Tolerability of Vabomere Compared to Best Available Therapy in Treating Serious Infections in Adults
Summary
The lay summary the sponsor registered on ClinicalTrials.gov.
Investigators
The overall officials registered on this study. Names that resolve to a FindMyKOL profile link to it; the rest are shown as registered.
- Karen Fusaro
Sponsor GmbH
Study Director - Keith Kaye
Wayne State University
Principal Investigator
A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.
Sites
50 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.
- Facility name not stated
Buenos Aires, Argentina
- Facility name not stated
Córdoba, Argentina
- Facility name not stated
La Plata, Argentina
- Facility name not stated
Mendoza, Argentina
- Facility name not stated
São José do Rio Preto, São Paulo, Brazil
- Facility name not stated
Belo Horizonte, Brazil
- Facility name not stated
Curitiba, Brazil
- Facility name not stated
Porto Alegre, Brazil
- Facility name not stated
São Paulo, Brazil
- Facility name not stated
São Paulo, Brazil
- Facility name not stated
São Paulo, Brazil
- Facility name not stated
Barranquilla, Colombia
- Facility name not stated
Bogotá, Colombia
- Facility name not stated
Medellín, Colombia
- Facility name not stated
Athens, Greece
- Facility name not stated
Athens, Greece
- Facility name not stated
Athens, Greece
- Facility name not stated
Thessaloniki, Greece
- Facility name not stated
Haifa, Israel
- Facility name not stated
Petah Tikva, Israel
- Facility name not stated
Ramat Gan, Israel
- Facility name not stated
Tel Aviv, Israel
- Facility name not stated
Bologna, Italy
- Facility name not stated
Florence, Italy
- Facility name not stated
Genova, Italy
- Facility name not stated
Pisa, Italy
- Facility name not stated
Rome, Italy
- Facility name not stated
Udine, Italy
- Facility name not stated
Manchester, United Kingdom
- Facility name not stated
Manchester, United Kingdom
- Facility name not stated
Hartford, Connecticut, United States
- Facility name not stated
Tampa, Florida, United States
- Facility name not stated
Augusta, Georgia, United States
- Facility name not stated
Chicago, Illinois, United States
- Facility name not stated
Chicago, Illinois, United States
- Facility name not stated
Evanston, Illinois, United States
- Facility name not stated
Indianapolis, Indiana, United States
- Facility name not stated
Detroit, Michigan, United States
- Facility name not stated
Royal Oak, Michigan, United States
- Facility name not stated
New Brunswick, New Jersey, United States
Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.
Drugs studied
The drug and biological interventions registered on this study, normalized to their RxNorm ingredient where possible.
Registration & key dates
Registry attributes as recorded on the ClinicalTrials.gov study record.
- Start
- 31 Jul 2014
- Primary completion
- 21 Jul 2017
- Completion
- 21 Jul 2017
- Last update posted
- 4 Mar 2019
- Registered enrollment
- 77
- Registry id
- NCT02168946
Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 4 Nov 2026. Registry facts are shown as registered by the study sponsor; FindMyKOL does not interpret them.